浙江医药(600216.SH)：XC2309注射液获得药物临床试验批准通知书

Core Viewpoint - Zhejiang Medicine (600216.SH) has received approval from the National Medical Products Administration for the clinical trial of XC2309 injection, indicating progress in its drug development pipeline [1] Company Summary - Zhejiang Medicine has successfully obtained the clinical trial approval for XC2309 injection, which meets the requirements for drug registration [1]